Fasenra 30 mg solution for injection in pre-filled pen *
Company:
AstraZeneca Pharmaceuticals (Ireland) DACStatus:
No Recent UpdateLegal Category:
Product subject to medical prescription which may not be renewed (A)Active Ingredient(s):
This medicinal product is subject to additional monitoring.
*Additional information is available within the SPC or upon request to the company
When a pharmaceutical company changes any document, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.
Updated on 15 July 2021
File name
20210708 SPC IE MT Fasenra PFS and PFP MELTEMI Update RSP 21 0008_1626348519.pdf
Reasons for updating
- Change to section 4.8 - Undesirable effects
Legal category:Product subject to medical prescription which may not be renewed (A)
Updated on 31 March 2021
File name
20210326 Package Leaflet IE MT Fasenra PFP 30 mg Nijmegen Change RSP 21 0004_1617204157.pdf
Reasons for updating
- Change to section 4 - how to report a side effect
- Change to section 6 - manufacturer
- Change to section 6 - date of revision
File name
20190627-uim-ifu-Fasenra-AI only-RSP 19 0041_1587458441.pdf
Reasons for updating
- Add New Doc
Updated on 21 April 2020
File name
20190627-uim-spc-Fasenra-PFS SA and AI-RSP 19 0039_1587458295.pdf
Reasons for updating
- New SPC for new product
Legal category:Product subject to medical prescription which may not be renewed (A)
Updated on 21 April 2020
File name
20190627-uim-pl-Fasenra-AI only-RSP 19 0038_1587458049.pdf
Reasons for updating
- New PIL for new product